Preparing Documentation to Support Clinical Supply Manufacture - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Preparing Documentation to Support Clinical Supply Manufacture
This article is written to assist clinical manufacturing representatives at pharmaceutical companies who are faced for the first time with outsourcing the manufacture of clinical supplies. The author describes the identification, writing, and execution of documents required to support the contract manufacture of products for clinical studies.


Pharmaceutical Technology


5. P.A. Josephs and M.A. Iacobucci, "Selecting a Contract Manufacturing Provider," Pharm. Technol., Contract Services (supplement), 72–80 (1999).

6. W. Lowry Caudill, "Making Outsourcing a Success: A View from Both Sides," Pharm.Technol., Contract Services (supplement), 20–26 (1999).

7. D. Feuerhelm and G.S. Blank, "Documentation: It's Not Just Paper Work," BioPharm International 14 (8), 18–21, 64 (2001).

8. V. Hedgecock, "Preparing for Preapproval Inspections at Contract Manufacturers," Amer. Pharm. Outsourcing 3 (6), 23–34 (Nov. 2002).

9. R.P. Blasini, "Quality Agreements between Pharmaceutical and Biopharmaceutical Companies and Their Contractors," BioPharm International 18 (4), 66–74 (2005).

10. D. Rosenkrantz, "Quality Considerations for Managing Contract Service Providers," Amer. Pharm. Outsourcing 3 (3), 20–24 (2002).

11. International Organization for Standardization, ISO 2859-1:1999: Sampling Procedures for Inspection by Attributes, Part I: Sampling Schemes Indexed by Acceptance Quality Limit (AQL) for Lot-by-Lot Inspection (ISO, Geneva, Switzerland, 1995).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here